Table 2.
IPA analysis enlisting top five canonical pathways and upstream regulators in TB-HIV and HIV gene sets
| Top pathways (upregulated) | p-value | Overlap | Overlapping Genes |
|---|---|---|---|
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 6.01E-06 | 6.3% (18/287) | SOCS3,ICAM1,TLR8,CEBPD, IRAK3,IL1R1, CREB5, PDGFC, FCGR1A, IL18R1, IL18RAP, IL1R2,FOS, NFKBIA,MAPK14,TLR5,TLR1,TCF7L2 |
| IL-10 Signaling | 3.24E-05 | 11.8% (8/68) | IL1R2,FOS, SOCS3, IL4R,NFKBIA, MAPK14,IL1R, IL18RAP |
| p38 MAPK Signaling | 5.71E-05 | 8.5% (10/117) | IL1R2, MAPK14,TIFA,DUSP1, MKNK1, IRAK3,IL1R1, CREB5, IL18RAP, HSPB1 |
| Toll-like Receptor Signaling | 3.68E-04 | 9.6% (7/73) | FOS,NFKBIA,MAPK1,TLR5, TLR1,TLR8, IRAK3 |
| Hepatic Fibrosis / Hepatic Stellate Cell Activation | 5.09E-04 | 6.1% (11/181) | IL1R2,IL4R, ICAM1,HGF, FGFR1,IGF1R, COL4A2,IL1R, IFNAR2, PDGFC, IL18RAP |
| Upstream Regulators (upregulated) | p-value of overlap | ||
| Immunoglobulin | 1.51E-13 | ||
| PGR | 3.23E-08 | ||
| Lipopolysaccharide | 4.31E-08 | ||
| CSF2 | 4.81E-07 | ||
| IL-1 | 4.98E-07 | ||
| EIF2 Signaling | 3.40E-08 | 7.5% (13/173) | RPS7,RPS6, RPL4, RPLP1, RPL23A, RPL22L1, RPL37,EIF4A2, RPL23,RPS17, RPS4,RPL13A,RPS11 |
| Primary Immunodeficiency Signaling | 6.06E-06 | 13.6% (6/44) | RFX5,LCK, ZAP70, CD8A,UNG, IGHD |
| B Cell Development | 1.67E-04 | 14.8% (4/27) | SPN,CD79B, HLA-DMB,IGHD |
| Granzyme A Signaling | 6.82E-04 | 17.6% (3/17) | PRF1,H1FX, APEX1 |
| Regulation of eIF4 and p70S6K Signaling | 7.64E-04 | 4.9% (7/143) | RPS7,RPS6, EIF4A2, RPS17,RPS4X, RPS11,ITGA4 |
| Upstream Regulators (downregulated) | p-value of overlap | ||
| MYCN | 2.72E-09 | ||
| Alefacept | 5.84E-08 | ||
| TCR | 2.59E-06 | ||
| Lipopolysaccharide | 2.89E-06 | ||
| IL-15 | 9.25E-06 |